[
  {
    "ts": "2026-01-28T12:48:58+00:00",
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "62d39b3a-c971-3378-8437-69454e7eb072",
      "content": {
        "id": "62d39b3a-c971-3378-8437-69454e7eb072",
        "contentType": "STORY",
        "title": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
        "description": "",
        "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
        "pubDate": "2026-01-28T12:48:58Z",
        "displayTime": "2026-01-28T12:48:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C1nJneUQiExdSmoCae_JSg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63PlXOZomCP8u1XunFvtlg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/64d2b01b91342b8aa8832daffb3a852f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/cms-selects-next-batch-of-15-high-cost-medicines-for-third-negotiation-cycle/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cms-selects-next-batch-15-124858672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "TAK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T13:20:26+00:00",
    "headline": "Gilead price target raised to $145 from $140 at Truist",
    "summary": "Truist raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst t",
    "url": "https://finance.yahoo.com/news/gilead-price-target-raised-145-132026163.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "2bc79c89-ed0c-36e8-a762-c7e757465c67",
      "content": {
        "id": "2bc79c89-ed0c-36e8-a762-c7e757465c67",
        "contentType": "STORY",
        "title": "Gilead price target raised to $145 from $140 at Truist",
        "description": "",
        "summary": "Truist raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst t",
        "pubDate": "2026-01-28T13:20:26Z",
        "displayTime": "2026-01-28T13:20:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-145-from-140-at-truist-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/helf4gKLfsGqfXh6T4C4dA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OJ7GAVnGpmjB26OOPLnbvw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-price-target-raised-145-132026163.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-price-target-raised-145-132026163.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:48:09+00:00",
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "4fce182c-2cef-3796-bb3c-381e42965b9d",
      "content": {
        "id": "4fce182c-2cef-3796-bb3c-381e42965b9d",
        "contentType": "STORY",
        "title": "Some of Pharma's Biggest Brands Face a New Reality",
        "description": "",
        "summary": "A government process quietly moves forward",
        "pubDate": "2026-01-28T14:48:09Z",
        "displayTime": "2026-01-28T14:48:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharmas-biggest-brands-face-reality-144809825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]